OQL025 / OnQuality Pharma - LARVOL DELTA

OnQuality Announces FDA Clearance of IND Application for OQL025 for the treatment of EGFR Inhibitor-Induced Acneiform Rash (PRNewswire) - "OnQuality Pharmaceuticals...announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for our OQL025 Investigational New Drug (IND) application, with an indication to treat Epidermal Growth Factor receptor (EGFR) inhibitor-induced acneiform rash, a common toxicity affecting patients treated with EGFR inhibitor therapy."

IND • Dermatology • Oncology

OQL025, a topical cream for the prevention of epidermal growth factor receptor inhibitor-induced skin rash (AACR 2023) - "Prevention of EGFRI-induced rash was studied with topically applied 3% or 6% OQRC184 or vehicle cream (CRM) in an SD rat EGFRI-induced rash model (oral afatinib 30 mg/kg (AF)), QD vs. vehicle (water (VW)). OQRC184, a prodrug designed for releasing tofacitinib into dermal layers, lacks inhibitory potential for a family of JAK kinases. OQL025 topical cream containing OQRC184 showed minimal systemic exposure for either OQRC184 or tofacitinib and effectively prevented/reduced EGFRI-induced rash in preclinical models."

Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • JAK1 • JAK2 • JAK3 • TYK2